MedTrace Logo

Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)

NCT07297290 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2025-12-22

No results posted yet for this study

Summary

Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.

Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.

Conditions

  • Obesity and Cardiovascular Risk
  • Insulin Resistance
  • Obesity (Body Mass Index >30 kg/m2)

Interventions

DRUG

Metformin

Metformin 500mg extended release tablets taken to a maximum of 1500mg once daily

DRUG

Placebo

Starch-based, identical looking placebo

Sponsors & Collaborators

  • Cures Within Reach

    collaborator OTHER

  • University Of Nigeria Teaching Hospital

    lead NETWORK

Principal Investigators

  • IFEYINWA D NNAKENYI, MD · University Of Nigeria Teaching Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-23
Primary Completion
2027-03-31
Completion
2027-09-30

Countries

  • Nigeria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07297290 on ClinicalTrials.gov